ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to optimize pretargeting parameters using pharmacokinetic and
imaging data for immuno-PET using anti-CEA x anti-HSG TF2 BsMAb and 150 MBq of 68Ga-IMP-288
peptide in MTC patients with abnormal Ct serum level after initial complete surgery and at
least one abnormal lesion